Plot No.367, Abhey Pur, Industrial Area Phase-1, Panchkula, Haryana 134109
Don't miss out on this limited-time offer to join our successful PCD Pharma network. Fill in your details below and our team will get in touch with you to discuss the best franchise opportunities tailored to your needs.
Ceftriaxone (500mg) + Tazobactum (62.5 mg) Injection
Therapeutic Category
Antibacterials, Antibiotic
Dosage Form
Injection
Packaging Type
Vial + Water
Packaging
562.520mg
Price
₹139/-
High-resolution images and Product visuals
Product overview and usage information
Detailed information and research documents
Fritcet TZ 562.50 Injection is a potent combination of ceftriaxone and tazobactam, designed to combat a wide range of bacterial infections. Ceftriaxone is a broad-spectrum cephalosporin antibiotic that works by inhibiting bacterial cell wall synthesis, leading to the destruction of susceptible bacteria. Tazobactam, a beta-lactamase inhibitor, enhances the efficacy of ceftriaxone by preventing certain bacteria from inactivating the antibiotic, thus broadening its antimicrobial activity. This formulation is particularly effective against infections caused by resistant strains, making it a valuable option in the treatment of serious infections.
Fritcet TZ is indicated for the treatment of various infections, including but not limited to pneumonia, urinary tract infections, skin and soft tissue infections, and intra-abdominal infections. It is administered through intravenous injection, ensuring rapid onset of action and effective therapeutic levels in the bloodstream.
Possible side effects include allergic reactions, gastrointestinal disturbances, and changes in liver function tests.
Effective for severe bacterial infections including pneumonia, UTIs, and skin infections.
Consult a healthcare professional before use, especially in cases of renal impairment or known allergies to beta-lactams. This injection is typically reserved for use in a hospital setting or under the supervision of a healthcare provider due to its potential for serious side effects and the need for monitoring during treatment. The dosing regimen will depend on the type and severity of the infection, as well as patient-specific factors such as age, weight, and renal function. As with all antibiotics, it is crucial to complete the prescribed course to prevent the development of resistance. Fritcet TZ 562.50 Injection represents a significant advancement in the management of complex bacterial infections, providing healthcare providers with a reliable tool in the ongoing battle against antibiotic-resistant pathogens. Always ensure appropriate laboratory tests and clinical assessments are conducted to tailor therapy to individual patient needs effectively.
Store at room temperature, away from direct sunlight and moisture.
Composition : Ceftriaxone (125mg) Injection
Composition : Ceftriaxone (1000mg)
Composition : Ceftriaxone (250mg)
Composition : Ceftriaxone (500mg)
Composition : Ceftriaxone (1000mg) + Sulbactam (500mg)
Composition : Ceftriaxone (250mg) + Sulbactam (125mg)
Composition : Ceftriaxone Sodium I.P. 1000mg + Tazobactam Sodium I.P. 125mg
Composition : Ceftriaxone (250mg) + Tazobactum (31.25mg)
Composition : Levofloxacin 500mg Infusion
Composition : Linezolid Intravenous Infusion I.P. 2mg Infusion
This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.
Ceftriaxone 500mg + Tazobactam 62.5mg Injection has strong demand in the hospital, anti-infective, and critical care segment, making it a valuable product for medical distributors, wholesalers, and pharma franchise partners focusing on advanced injectable antibiotics and institutional healthcare portfolios.
Medical distributors and agencies can benefit from consistent demand for moderate to severe bacterial infection management under medical supervision. Ceftriaxone 500mg is a third-generation cephalosporin antibiotic with broad-spectrum antibacterial activity Tazobactam 62.5mg is a beta-lactamase inhibitor that helps enhance the effectiveness of ceftriaxone against resistant bacterial strains Commonly prescribed for respiratory tract infections, urinary tract infections, skin and soft tissue infections, intra-abdominal infections, gynecological infections, and other susceptible bacterial infections Widely used in hospitals, nursing homes, and critical care settings Injectable formulation provides rapid therapeutic action and effective infection management This strengthens a robust anti-infective and hospital-care portfoli
Yes, Cafoli LifeCare Pvt Ltd offers PCD pharma franchise opportunities for Ceftriaxone 500mg + Tazobactam 62.5mg Injection with promotional support, monopoly rights, attractive packaging, and competitive pricing for distributors and wholesalers.
Wholesalers and medical agencies benefit from strong hospital demand, institutional procurement opportunities, repeat orders, reliable supply chain support, high market acceptance, and attractive margins in the injectable antibiotic segment.
Interested distributors, stockists, and wholesalers can contact Cafoli LifeCare Pvt Ltd to explore PCD pharma franchise opportunities, discuss pricing and business terms, obtain monopoly territory rights, and benefit from comprehensive marketing support, quality pharmaceutical products, and a dependable supply chain to grow their business successfully.